TIDMOBD
Oxford BioDynamics PLC
15 November 2017
15 November 2017
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
Oxford BioDynamics presents latest immunotherapy data at the NIH
Biomarker Consortium Cancer Steering Committee Annual Symposium, in
Washington, DC
EpiSwitch(TM) technology shows consistent profile of predictive
biomarkers for response to immune checkpoint inhibitor therapy
Oxford BioDynamics Plc (AIM: OBD), a biotechnology company
focused on the discovery and development of epigenetic biomarkers
based on regulatory genome architecture, for use within the
pharmaceutical and biotechnology industry, presented its latest
results at the annual meeting of the Foundation for National
Institute for Health (FNIH) Biomarker Consortium Cancer Steering
Committee, held in Washington, DC on 6-7 November 2017.
In the session dedicated to immune-oncology biomarkers, Dr A.
Akoulitchev, Chief Scientific Officer of OBD, presented the results
from three independent studies which showed a consistent profile of
epigenetic markers for response to immune checkpoint inhibitor
therapies, including anti-PD-L1 therapy Keytruda (Pembrolizumab)
and several other anti-PD-L1 assets in two disease indications.
Blind validation of an independent cohort of base line patients
treated with an anti-PD-L1 therapeutic showed that OBD's
EpiSwitch(TM) technology could predict response to treatment with a
83% positive predictive value (PPV). The biological relevance of
identified epigenetic regulatory biomarkers for immunotherapy was
strongly supported by their role in T-cell reinvigoration,
survival, and proliferation to tumour burden.
It was also shown that a sub-group of the predictive
EpiSwitch(TM) markers for response to treatment, identified and
verified in over 57 patients, were associated to genes which are
downstream of Interferon gamma stimulation. Another subgroup of
biomarkers revealed high concordance with regulatory controls of
MHC II receptors, known to play critical role in response to
anti-PD-1 therapy. Full scope of the patient cohorts analysed by
OBD will exceed 180 patients.
Further implications of EpiSwitch(TM) based approaches to
patient stratifications were also discussed, including exclusion of
patients with hyper progression and other side effects to
immunotherapy.
The Biomarkers Consortium is a public-private biomedical
research partnership managed by the FNIH that endeavours to
discover, develop, and seek regulatory approval for biological
markers, known as biomarkers, to support new drug development,
preventive medicine, and medical diagnostics.
The Steering Committees are responsible for identifying and
moving forward promising pre-competitive biomarkers projects for
implementation by The Biomarkers Consortium, as well as overseeing
each individual project under its purview. The members of each
Steering Committee represent a variety of sectors, including
academia, government, industry and not-for-profit/advocacy
organisations. OBD is represented at the Steering Committees
covering Cancer, Inflammation & Immunity, and Neuroscience by
Dr Claudio Carini, an Advisor to OBD and a member of the Company's
Scientific Advisory Panel.
Christian Hoyer Millar, CEO of Oxford BioDynamics,
commented:
"We are delighted with the progress and consistent quality of
biomarker data that our EpiSwitch(TM) platform has been able to
deliver in these immunotherapy studies. The immunotherapy biomarker
programme has developed into a high value area of interest for OBD
and we are committed to offering quick and robust practical
solutions for patient stratifications for all the therapy
programmes we are working on.
We have been actively expanding our intellectual property
footprint, and with our technology demonstrating consistent
practical solutions, we see immunotherapy as a strategic line of
biomarker development for our Company, which we believe has the
potential to further improve clinical outcomes and the standard of
patient care in this area.
We believe that being among a network of many reputable
companies and institutions will be beneficial as we continue to
progress towards our strategic aim of becoming the industry
standard for chromosome conformations and biomarkers in genome
architecture."
For further details contact:
Oxford BioDynamics Plc +44 (0)1865 518910
Christian Hoyer Millar,
CEO
Paul Stockdale, CFO
FTI Consulting +44 (0)20 3727 1000
Financial Public Relations
Advisor
Julia Phillips
Brett Pollard
Natalie Garland-Collins
Stifel Nicolaus Europe
Limited +44 (0)20 7710 7600
Nominated Advisor and
Broker
David Arch
Jonathan Senior
Peter Lees
Ben Maddison
Shore Capital +44 (0)20 7408 4090
Joint Broker
Stephane Auton
Edward Mansfield
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
revenue--generating biotechnology company focused on the discovery
and development of novel epigenetic biomarkers for use within the
pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes, and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the
London Stock Exchange's AIM under the ticker "OBD". For more
information please visit www.oxfordbiodynamics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABLBDBDGBBGRS
(END) Dow Jones Newswires
November 15, 2017 02:01 ET (07:01 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024